Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada.
COVID-19
Disease-modifying therapy
Multiple sclerosis
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
01
11
2021
revised:
14
12
2021
accepted:
06
01
2022
pubmed:
15
1
2022
medline:
3
3
2022
entrez:
14
1
2022
Statut:
ppublish
Résumé
To report clinical characteristics and outcomes of people with multiple sclerosis (PwMS) who developed COVID-19 infection in Toronto, Canada. Descriptive, retrospective, single-center study that included all known PwMS at the St. Michael's Hospital MS Clinic who had PCR-confirmed COVID-19 infection between March 2020 and May 2021. Of 7000 PwMS in our clinic, 80 (1.1%) tested positive for SARS-CoV-2. Fifty-four (67.5%) were on disease-modifying therapy (DMT) without over-representation of any single treatment. Seventy-one patients (88.8%) had mild symptoms, but nine (11.3%) were hospitalized and one 70-year-old male patient not on treatment died. Of those hospitalized, one-third were treated with ocrelizumab. In Toronto, PwMS did not appear to have higher prevalence of COVID-19 infection compared to the general population, but disease severity may be affected by DMT use. Our findings add to the accumulating global data regarding COVID-19 infection in PwMS.
Identifiants
pubmed: 35030366
pii: S2211-0348(22)00024-4
doi: 10.1016/j.msard.2022.103509
pmc: PMC8741626
pii:
doi:
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
103509Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.